INS and Hyperglycemia: As a consequence, we observed that MSI-1436-treated horses exhibited lower circulating concentrations of insulin and glucose compared to untreated animals, which displayed critical hyperinsulinemia, hyperglycaemia and hypoadiponectinemia as prominent EMS clinical manifestations.